Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy

Journal of Neuro-Oncology, 04/09/2012

The phase I study was closed during enrollment of the first 6–patient cohort because of the high incidence (60 %) of early radiation toxicity. The authors do not recommend the seed–wafer therapy for newly diagnosed glioblastoma multiforme (GBM) patients but rather reserve this as salvage therapy for select patients with recurrent GBM.

Print Article Summary Cat 2 CME Report